References

Antibody therapy of cancer

10.1038/nrc3236 · 2012 · External reference

Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy

1997 · External reference

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma

2002 · External reference

Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors

1983 · External reference

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

10.1016/j.ccr.2005.03.003 · 2005 · External reference

The biological properties of cetuximab

10.1016/j.critrevonc.2008.07.006 · 2008 · External reference

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

10.1158/1078-0432.ccr-07-0865 · 2007 · External reference

Immune complex–mediated antigen presentation induces tumor immunity

10.1172/jci0215640 · 2002 · External reference

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses

10.1038/mt.2012.184 · 2013 · External reference

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo

10.4049/jimmunol.168.5.2240 · 2002 · External reference

Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells

10.1158/0008-5472.can-16-2774 · 2017 · External reference

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

10.1158/1078-0432.ccr-12-2426 · 2013 · External reference

Oncolytic viruses in cancer treatment: a review

10.1001/jamaoncol.2016.2064 · 2017 · External reference

Oncolytic viruses: a new class of immunotherapy drugs

10.1038/nrd4663 · 2015 · External reference

New generation of oncolytic herpes virus

10.2174/1573394712666160128201756 · 2015 · External reference

Oncolytic virotherapy

10.1038/nbt.2287 · 2012 · External reference

Talimogene laherparepvec improves durable response rate in patients with advanced melanoma

10.1200/jco.2014.58.3377 · 2015 · External reference

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing

10.1073/pnas.101136398 · 2001 · External reference

Efficacy of a third-generation oncolytic herpes virus G47Δ in advanced stage models of human gastric cancer

10.1016/j.omto.2020.03.022 · 2020 · External reference

Neoadjuvant use of oncolytic herpes virus G47Δ enhances the antitumor efficacy of radiofrequency ablation

10.1016/j.omto.2020.08.010 · 2020 · External reference

Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis

10.1016/j.omto.2021.06.008 · 2021 · External reference

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition through dynamic intratumoral immune modulation

10.1016/j.omto.2021.05.004 · 2021 · External reference

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma

10.1016/j.omto.2021.10.012 · 2021 · External reference

Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial

10.1038/s41591-022-01897-x · 2022 · External reference

A phase I/II study of triple-mutated oncolytic herpes virus G47Δ in patients with progressive glioblastoma

10.1038/s41467-022-31262-y · 2022 · External reference

In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity

2001 · External reference

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

10.1016/j.ccell.2014.09.007 · 2014 · External reference

Roles for innate immunity in combination immunotherapies

10.1158/0008-5472.can-17-1340 · 2017 · External reference

Type I interferons in anticancer immunity

10.1038/nri3845 · 2015 · External reference

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

10.1200/jco.2009.24.6116 · 2010 · External reference

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

10.3389/fimmu.2023.1308890 · 2023 · External reference

The quest to overcome resistance to EGFR-targeted therapies in cancer

10.1038/nm.3388 · 2013 · External reference

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

10.1089/10430349950016483 · 1999 · External reference

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

10.1126/scitranslmed.3008095 · 2014 · External reference

Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade

10.1158/1078-0432.ccr-17-0681 · 2017 · External reference

Integrating oncolytic viruses in combination cancer immunotherapy

10.1038/s41577-018-0014-6 · 2018 · External reference

Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth

10.1016/j.omto.2019.04.004 · 2019 · External reference

Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients

10.1158/1078-0432.ccr-15-2971 · 2016 · External reference

Mouse and human FcR effector functions

10.1111/imr.12350 · 2015 · External reference

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

10.3389/fimmu.2015.00368 · 2015 · External reference

Oncolytic adenovirus expressing monoclonal antibody trastuzumab for treatment of HER2-positive cancer

10.1158/1535-7163.mct-15-0819 · 2016 · External reference

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

10.1038/leu.2015.88 · 2015 · External reference

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

10.1080/2162402x.2015.1080414 · 2016 · External reference

The head and neck cancer immune landscape and its immunotherapeutic implications

10.1172/jci.insight.89829 · 2016 · External reference

Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy

10.1038/onc.2016.231 · 2017 · External reference

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts

10.1158/0008-5472.can-04-3344 · 2005 · External reference

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs

10.1172/jci34333 · 2008 · External reference

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses

10.1016/j.ccr.2013.12.004 · 2014 · External reference

Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies

10.1016/j.it.2017.11.006 · 2018 · External reference

The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation

10.1084/jem.20040317 · 2004 · External reference

Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms

10.3390/ijms18112420 · 2017 · External reference